Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
FLGT Stock | USD 17.34 0.38 2.24% |
Slightly above 57% of all Fulgent Genetics' private investors are looking to take a long position. The analysis of overall sentiment of trading Fulgent Genetics stock suggests that some investors are interested at this time. Fulgent Genetics' investing sentiment can be driven by a variety of factors including economic data, Fulgent Genetics' earnings reports, geopolitical events, and overall market trends.
Fulgent |
EL MONTE, Calif., February 13, 2024--Fulgent Genetics, Inc. , a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024. Management will host a conference call for the investment community the same day at 830 AM ET to discuss the re
Read at finance.yahoo.com
Fulgent Genetics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Fulgent Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fulgent Genetics Fundamental Analysis
We analyze Fulgent Genetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Fulgent Genetics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Fulgent Genetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fulgent Genetics stock to make a market-neutral strategy. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics with similar companies.
Peers
Fulgent Genetics Related Equities
ILMN | Illumina | 1.65 | ||||
EXAS | EXACT Sciences | 0.58 | ||||
CDNA | Caredx | 0.43 | ||||
DHR | Danaher | 0.34 | ||||
TMO | Thermo Fisher | 0.17 | ||||
GH | Guardant Health | 0.00 | ||||
A | Agilent Technologies | 0.03 | ||||
WAT | Waters | 0.07 | ||||
TWST | Twist Bioscience | 0.07 | ||||
CRL | Charles River | 0.25 | ||||
MTD | Mettler Toledo | 0.29 | ||||
TTOO | T2 Biosystms | 0.40 | ||||
NTRA | Natera | 1.67 |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.